Skip to main content

Telomerase Inhibition in Cancer Therapeutics: Molecular-Based Approaches

Buy Article:

$63.00 plus tax (Refund Policy)

Current standard cancer therapies (chemotherapy and radiation) often cause serious adverse off-target effects. Drug design strategies are therefore being developed that will more precisely target cancer cells for destruction while leaving surrounding normal cells relatively unaffected. Telomerase, widely expressed in most human cancers but almost undetectable in normal somatic cells, provides an exciting drug target. This review focuses on recent pharmacogenomic approaches to telomerase inhibition. Antisense oligonucleotides, RNA interference, ribozymes, mutant expression, and the exploitation of differential telomerase expression as a strategy for targeted oncolysis are discussed here in the context of cancer therapeutics. Reports of synergism between telomerase inhibitors and traditional cancer therapeutic agents are also analyzed.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: RNAi; Telomerase inhibition; antisense; dominant-negative hTERT; hTERT; hTR; mutant-template telomerase RNA; ribozyme

Document Type: Research Article

Affiliations: Department of Biology, 175 Campbell Hall, 1300 University Boulevard, University of Alabama at irmingham, Birmingham, AL 35294-1170, USA.

Publication date: 01 October 2006

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more